Relapsed/refractory immune-mediated kidney disease

Clinical trials for Relapsed/refractory immune-mediated kidney disease explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory immune-mediated kidney disease trials appear

Sign up with your email to follow new studies for Relapsed/refractory immune-mediated kidney disease, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Engineered immune cells take on kidney disease in early trial

Disease control Recruiting now

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…

Matched conditions: RELAPSED/REFRACTORY IMMUNE-MEDIATED KIDNEY DISEASE

Early phase 1 • Sponsor: Changhai Hospital • Aim: Disease control

Last updated Jun 27, 2026 09:02 UTC

Relapsed/refractory immune-mediated kidney disease

Get alerted when new Relapsed/refractory immune-mediated kidney disease trials appear

Engineered immune cells take on kidney disease in early trial